Compare Badger Meter Inc (BMI) vs TG Therapeutics Inc (TGTX) Price & Performance

Badger Meter (BMI) trades at $134.77, down 1.22% amid bearish technical signals and mixed quarterly results. The stock shows strong profitability with 14.27% net margins and 18.48% ROE, though valuation appears elevated with a P/E of 31.78. Recent news highlights multiple class-action lawsuits filed against the company, creating investor uncertainty despite insider buying activity and institutional position increases.

BMI faces near-term headwinds from legal challenges and earnings misses, but maintains solid fundamentals and analyst consensus target of $155.20 suggests 15% upside potential. The key risk remains resolution of securities litigation, while the company's strong cash flow generation and market position in water technology provide long-term stability.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.